Hostname: page-component-586b7cd67f-g8jcs Total loading time: 0 Render date: 2024-11-22T20:16:29.508Z Has data issue: false hasContentIssue false
  • English
  • Français

The psychological impact of disclosing amyloid status to Japanese elderly: a preliminary study on asymptomatic patients with subjective cognitive decline

Published online by Cambridge University Press:  02 November 2017

Taisei Wake ,
Hajime Tabuchi ,
Kei Funaki ,
Daisuke Ito ,
Bun Yamagata ,
Takahito Yoshizaki ,
Masashi Kameyama ,
Tadaki Nakahara ,
Koji Murakami  and
Masahiro Jinzaki
...Show all authors
Taisei Wake
Affiliation:
Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan
Hajime Tabuchi*
Affiliation:
Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan
Kei Funaki
Affiliation:
Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan
Daisuke Ito
Affiliation:
Department of Neurology, Keio University School of Medicine, Tokyo, Japan
Bun Yamagata
Affiliation:
Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan
Takahito Yoshizaki
Affiliation:
Department of Neurology, Keio University School of Medicine, Tokyo, Japan
Masashi Kameyama
Affiliation:
Department of Diagnostic Radiology, Keio University School of Medicine, Tokyo, Japan Department of Diagnostic Radiology, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Tokyo, Japan
Tadaki Nakahara
Affiliation:
Department of Diagnostic Radiology, Keio University School of Medicine, Tokyo, Japan
Koji Murakami
Affiliation:
Department of Radiology, Juntendo University School of Medicine, Tokyo, Japan
Masahiro Jinzaki
Affiliation:
Department of Diagnostic Radiology, Keio University School of Medicine, Tokyo, Japan
Masaru Mimura
Affiliation:
Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan
*
Correspondence should be addressed to: Hajime Tabuchi, MD, PhD, Department of Neuropsychiatry, Keio University School of Medicine, Shinanomachi 35, Shinjuku-ku, Tokyo 160-8582, Japan. Phone: +81-3-3353-1211 (ext. 62454); Fax: +81-3-5379-0187. Email: [email protected].
Get access Rights & Permissions [Opens in a new window]

Abstract

In Japan, 4.6 million people are living with dementia and the number is expected to rise to 7 million by 2025. Amyloid-β (Aβ) positron emission tomography (PET) is used for cognitively normal Japanese people with or without subjective cognitive decline (SCD) for the purpose of clinical trials or diagnosis. Nevertheless, no empirical studies have been conducted on the safety of disclosing amyloid status to such populations. We conducted amyloid PET imaging on 42 participants (Aβ positive (n = 10) and negative (n = 32)). State anxiety and depression were measured at pre- and post-disclosure, and test-related distress at post-disclosure. Mean state anxiety and depression scores were below the cut-off through pre- and post-disclosure in the Aβ positive and negative groups. State anxiety and depression did not change over time and were not different between groups. Mean test-related distress scores were within normal limits at post-disclosure in both groups. No significant difference was found between groups. Disclosing Aβ positive results did not cause greater mood disturbance than negative results in a short period of time. The short-term psychological safety of disclosing Aβ PET results to asymptomatic Japanese adults with SCD was indicated.

Keywords

Alzheimer diseasebiomarkersethicspositron emission tomography (PET)memory clinics
Type
Brief Report
Information
International Psychogeriatrics , Volume 30 , Issue 5: Issue Theme: Brain Imaging , May 2018 , pp. 635 - 639
Copyright
Copyright © International Psychogeriatric Association 2017 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Amariglio, R. E. et al. (2015). Subjective cognitive concerns, amyloid-beta, and neurodegeneration in clinically normal elderly. Neurology, 85, 56–62.Google Scholar
Balash, Y., Mordechovich, M., Shabtai, H., Giladi, N., Gurevich, T. and Korczyn, A. D. (2013). Subjective memory complaints in elders: depression, anxiety, or cognitive decline?. Acta Neurologica Scandinavica, 127, 344–350.Google Scholar
Burns, J. M., Johnson, D. K., Liebmann, E. P., Bothwell, R. J., Morris, J. K. and Vidoni, E. D. (2017). Safety of disclosing amyloid status in cognitively normal older adults. Alzheimers and Dementia, 13, 1024–1030.Google Scholar
Editorial (2017). Solanezumab: too late in mild Alzheimer's disease?. The Lancet Neurology, 16, 97.Google Scholar
Japanese Society of Nuclear Medicine, Japan Society for Dementia Research, and Japanese Society of Neurology (2015). Guideline for appropriate use of amyloid imaging. Available at: http://www.jsnm.org/japanese/15-06-09; accessed 20 March 2017 (in Japanese).Google Scholar
Jessen, F. et al. (2014). A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement, 10, 844–852.Google Scholar
Johnson, K. A. et al. (2013). Appropriate use criteria for amyloid PET: a report of the Amyloid imaging task force, the society of nuclear medicine and molecular imaging, and the alzheimer's association. Alzheimers and Dementia, 9, e-1-16.Google Scholar
Lim, Y. Y., Maruff, P., Getter, C. and Snyder, P. J. (2016). Disclosure of positron emission tomography amyloid imaging results: a preliminary study of safety and tolerability. Alzheimers and Dementia, 12, 454–458.Google Scholar
Ministry of Health, L., and Welfare (2015). Comprehensive Strategy to Accelerate Dementia Measures (New Orange Plan). Available at: http://www.mhlw.go.jp/stf/houdou/2r9852000002iau1-att/2r9852000002iavi.pdf; accessed 20 March 2017 (in Japanese).Google Scholar
Neuraceq® Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/204677s000lbl.pdf; accessed 20 March 2017.Google Scholar
Perrotin, A., Mormino Ec Fau - Madison, C. M., Madison Cm Fau - Hayenga, A. O., Hayenga Ao Fau - Jagust, W. J. and Jagust, W. J. (2012). Subjective cognition and amyloid deposition imaging: a Pittsburgh Compound B positron emission tomography study in normal elderly individuals. Archives of Neurology, 69, 223–229.Google Scholar
Reiman, E. M. et al. (2016). CAP: advancing the evaluation of preclinical Alzheimer disease treatments. Nature Review Neurology, 12, 56–61.Google Scholar
Sperling, R. A. et al. (2011). Toward defining the preclinical stages of Alzheimer's disease: recommendations from the national institute on aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers and Dementia, 7, 280–292.Google Scholar
Umegaki, H., Onishi, J., Suzuki, Y., Endo, H. and Iguchi, A. (2007). Attitudes toward disclosing the diagnosis of dementia in Japan. International Psychogeriatrics, 19, 253–265.Google Scholar
Witte, M. M. et al. (2015). Clinical use of amyloid PET neuroimaging: practical and bioethical considerations. The American Journal of Geriatric Psychiatry, 23, S150–S151.Google Scholar